Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Fierce Pharma
Nature retracts provocative PD-1 time-of-day study
The Nature Medicine editors lost confidence in the viral study “due to the amount and nature of the problems identified,” a retraction note shows.
Angus Liu
Jun 24, 2026 11:00am
Fierce Pharma
Akeso's 34% overall survival win comes with caveats
May 31, 2026 8:00am
OSE turns up the heat on ovarian cancer with phase 2 win
May 22, 2026 7:14am
Fierce Pharma
ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS
May 21, 2026 5:00pm
Merck inks Keytruda supply pact to support Exelixis cancer trial
May 19, 2026 9:38am
Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data
May 11, 2026 10:06am